EndoSpan
Stent Graft Systems for Aneurysms and Dissections
Company Overview
Snapshot
Founded in August 2008 by Alon Shalev and Rafi Benary, EndoSpan operates with 51–200 employees. The company has secured funding across 5 rounds from 5 investors. In May 2026, EndoSpan was acquired by Artivion.
Business overview
EndoSpan develops low-profile stent graft systems designed for treating aneurysms and dissections throughout the aorta, including infrarenal, visceral, and thoracic regions. The company's core products, HORIZON and NEXUS, aim to make the treatment of aortic lesions simpler and less invasive, providing options for patients with limited alternatives. EndoSpan serves the medical devices market within the Health Tech & Life Sciences sector, focusing on cardiovascular and surgical applications.
Strategic signal
In May 2026, EndoSpan was acquired by Artivion, following FDA approval for its aortic repair system. This acquisition signals a significant validation of EndoSpan's technology and market potential, indicating a successful exit for investors and a strategic expansion for Artivion in the cardiovascular medical device space.
Company Intelligence Q&A
- What is EndoSpan's primary focus?
- EndoSpan develops stent graft systems for treating aneurysms and dissections in the aorta, including infrarenal, visceral, and thoracic areas, aiming for less invasive treatment options.
- When was EndoSpan acquired?
- EndoSpan was acquired by Artivion in May 2026, following FDA approval for its aortic repair system.
- What is the NEXUS system?
- The NEXUS is an aortic stent graft system from EndoSpan that offers a modular, minimally invasive endovascular solution for patients with aneurysms in the ascending aorta or aortic arch.
- When did the NEXUS system receive FDA Breakthrough Device Designation?
- The NEXUS aortic arch stent graft system received FDA Breakthrough Device Designation in April 2020.
- When did EndoSpan receive CE Mark for its HORIZON system?
- EndoSpan received the CE Mark for its HORIZON EVAR System in March 2018, based on clinical and pivotal data to treat abdominal aortic aneurysm.